Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Infectious Diseases, Ruijin Hospital, Jiaotong University, Shanghai, China.
Clin Microbiol Infect. 2016 Jun;22(6):571.e5-9. doi: 10.1016/j.cmi.2016.02.002. Epub 2016 Feb 18.
Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p <0.001; PEG-IFN add-on: -3.16 vs. -1.83 IU/mL, p <0.001) and in patients with vs. without hepatitis B surface antigen (HBsAg) response (ETV: -2.60 vs. -1.74 log U/mL, p <0.001; PEG-IFN add-on: -2.38 vs. -2.15 log U/mL, p = 0.31). HBcrAg was associated with combined response (adjusted odds ratio 0.3, 95% confidence interval 0.2-0.5, p <0.001), but was not superior to quantitative HBsAg (qHBsAg).
乙型肝炎核心相关抗原 (HBcrAg) 是一种新的血清标志物，可能有助于监测慢性乙型肝炎感染。本研究对 175 例乙型肝炎 e 抗原阳性患者进行了研究，这些患者接受恩替卡韦 (ETV) 单药或联合聚乙二醇干扰素 (PEG-IFN) 治疗。与无联合应答的患者相比，有联合应答的患者的 HBcrAg 下降幅度更大（ETV：-3.22 与-1.71 log U/mL，p <0.001；PEG-IFN 加用：-3.16 与-1.83 IU/mL，p <0.001），与无乙型肝炎表面抗原（HBsAg）应答的患者相比，有 HBsAg 应答的患者的 HBcrAg 下降幅度更大（ETV：-2.60 与-1.74 log U/mL，p <0.001；PEG-IFN 加用：-2.38 与-2.15 log U/mL，p = 0.31）。HBcrAg 与联合应答相关（调整后的优势比 0.3，95%置信区间 0.2-0.5，p <0.001），但不如定量 HBsAg (qHBsAg) 。
